Clinical Trials Sponsored by Repros Therapeutics Inc.

Total 2963 results

Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Androxal

Bioequivalence

United States
Repros Therapeutics Inc.

Completed

Crossover Study of the Safety and PK Properties of Proellex®

Pharmacokinetics

United States
Repros Therapeutics Inc.

Terminated

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

Endometriosis

United States
Repros Therapeutics Inc.

Completed

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Terminated

An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Investigate Absorption, Metabolism and Excretion of [14C}-Proellex Following Single Oral Dose in Healthy Females

ABSORPTION | METABOLISM | EXCRETION

United States
Repros Therapeutics Inc.

Withdrawn

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Uterine Fibroids

United States, Brazil
Repros Therapeutics Inc.

Completed

A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects

Healthy
Repros Therapeutics Inc.

Completed

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

Obesity | Acquired Hypogonadotropic Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal

Pharmacokinetics

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Oral Administration

Healthy

United States
Repros Therapeutics Inc.

Completed

Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

Impaired Liver Function

United States
Repros Therapeutics Inc.

Terminated

Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States, Mexico
Repros Therapeutics Inc.

Terminated

Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal

Normal Volunteers
Repros Therapeutics Inc.

Completed

Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males

Drug-drug Interaction

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism (ZA-003Ext)

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Withdrawn

Open-Label Extension Study to ZPE-202

Endometriosis

United States
Repros Therapeutics Inc.

Completed

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

Hypogonadism | Low Testosterone

United States
Repros Therapeutics Inc.

Terminated

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

Proellex® Pharmacokinetic Bridging Study II (PK)

Healthy

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism

Effect of Treatment on Bone Mineral Density

United States
Repros Therapeutics Inc.

Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Terminated

Study to Evaluate Menses Induction in Women Administered Proellex

Amenorrhea

United States
Repros Therapeutics Inc.

Terminated

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Renal Impairment

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis

Endometriosis

United States
Repros Therapeutics Inc.

Completed

Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects

Drug Interactions

United States
Repros Therapeutics Inc.

Terminated

Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids

Uterine Fibroids

United States
Repros Therapeutics Inc.

Terminated

Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids

Anemia | Uterine Fibroids

Mexico
Repros Therapeutics Inc.

Terminated

Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids

Anemia | Uterine Fibroids

United States
Repros Therapeutics Inc.

Completed

A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal

Pharmacokinetics | Tolerability

United States
Repros Therapeutics Inc.

Completed

A Safety and Pharmacokinetic Study of Proellex® (PK)

Healthy

United States
Repros Therapeutics Inc.

Completed

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

Secondary Hypogonadism

United States
Repros Therapeutics Inc.

Completed

Determination of the Lowest, Safe and Effective Dose of Proellex

Amenorrhea

United States

3

Subscribe